PDCD1 and head and neck squamous cell carcinoma: Recently, Ho et al. reported that pretreatment absolute lymphocyte count (ALC) was associated with progression-free survival (PFS) of recurrent or metastatic HNSCC treated with PD-1 inhibitor [7].